Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis

Background: Cancer induced chronic inflammation and cancer drugs effects on the vascular system can lead to rapidly progressing atherosclerotic burden. Statins drugs are known to reduce atherosclerotic plaque burden and inflammation. We studied outcomes of statins for anthracycline-related cardiac d...

詳細記述

書誌詳細
出版年:American Journal of Preventive Cardiology
主要な著者: Mubashar Karamat, Bilal Hussain, Munis Mahboob Ahmed, Mohammad Hamza, Junaid Mir, Ayedh Alamri, Aimen Shafiq, Yasar Sattar, Muhammad Zia Khan, Harshith Thyagaturu, Karthik Gonuguntla, Birjesh D Patel
フォーマット: 論文
言語:英語
出版事項: Elsevier 2024-12-01
主題:
オンライン・アクセス:http://www.sciencedirect.com/science/article/pii/S2666667724002423
_version_ 1849829680578822144
author Mubashar Karamat
Bilal Hussain
Munis Mahboob Ahmed
Mohammad Hamza
Junaid Mir
Ayedh Alamri
Aimen Shafiq
Yasar Sattar
Muhammad Zia Khan
Harshith Thyagaturu
Karthik Gonuguntla
Birjesh D Patel
author_facet Mubashar Karamat
Bilal Hussain
Munis Mahboob Ahmed
Mohammad Hamza
Junaid Mir
Ayedh Alamri
Aimen Shafiq
Yasar Sattar
Muhammad Zia Khan
Harshith Thyagaturu
Karthik Gonuguntla
Birjesh D Patel
author_sort Mubashar Karamat
collection DOAJ
container_title American Journal of Preventive Cardiology
description Background: Cancer induced chronic inflammation and cancer drugs effects on the vascular system can lead to rapidly progressing atherosclerotic burden. Statins drugs are known to reduce atherosclerotic plaque burden and inflammation. We studied outcomes of statins for anthracycline-related cardiac dysfunction (ARCD). Methods: We conducted an online systematic search on PubMed and Embase to identify studies assessing statins' role in alleviating ARCD. We selected 9 studies that had patients with ARCD and use of statins. We primarily focused on outcomes including incidence of heart failure (HF), mean changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), and end-systolic volume (LVESV) from baseline. Odds ratios (OR) were calculated using a random effect model in R-statistics. Results: Among 9 studies with a total of 2784 patients we noticed a significant reduction in the incidence of HF among patients administered statins, with an OR of 0.52 (95 % CI 0.37-0.74, p < 0.0003), indicating a substantial protective effect. However, the mean changes in EF, LVEDV, and LVESV from baseline, represented by Hedges's g of 1.09 (95 % CI -0.40 to 2.57, p = 0.15), 0.91 (95 % CI -1.69 to 3.51, p = 0.47), and 1.32 (95 % CI -2.30 to 4.94, p = 0.49) respectively, were not statistically significant. (Figure 1). Conclusion: Our meta-analysis confirms statins' effectiveness in reducing risk of ARCD. However, their influence on EF, LVEDV, and LVESV remains uncertain, warranting further study.
format Article
id doaj-art-65df04af007d4ead8095cd074beefeb7
institution Directory of Open Access Journals
issn 2666-6677
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
spelling doaj-art-65df04af007d4ead8095cd074beefeb72025-08-20T01:28:58ZengElsevierAmerican Journal of Preventive Cardiology2666-66772024-12-012010087410.1016/j.ajpc.2024.100874Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysisMubashar Karamat0Bilal Hussain1Munis Mahboob Ahmed2Mohammad Hamza3Junaid Mir4Ayedh Alamri5Aimen Shafiq6Yasar Sattar7Muhammad Zia Khan8Harshith Thyagaturu9Karthik Gonuguntla10Birjesh D Patel11Department of Internal Medicine, Ascension Saint Francis Hospital, Evanston, IL, USADivision of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH, USADepartment of Internal Medicine, Springfield Regional Medical Center, OHDepartment of Internal Medicine, Albany Medical Center, Albany, NYDepartment of Internal Medicine, University of Missouri, Columbia, MO, USA.Department of Cardiovascular Department, Tufts Medical Center, Boston, USADepartment of Internal Medicine, Dow University of Health Sciences, PakistanDepartment of Cardiology, West Virginia University, Morgantown, WV, USADepartment of Cardiology, West Virginia University, Morgantown, WV, USADepartment of Cardiology, West Virginia University, Morgantown, WV, USADepartment of Cardiology, West Virginia University, Morgantown, WV, USADepartment of Cardiology, West Virginia University, Morgantown, WV, USA; Corresponding author at: Cardiology Department, West Virginia University, Morgantown, WV, Address: 1 Medical Center Dr, Morgantown, WV 26506, USA.Background: Cancer induced chronic inflammation and cancer drugs effects on the vascular system can lead to rapidly progressing atherosclerotic burden. Statins drugs are known to reduce atherosclerotic plaque burden and inflammation. We studied outcomes of statins for anthracycline-related cardiac dysfunction (ARCD). Methods: We conducted an online systematic search on PubMed and Embase to identify studies assessing statins' role in alleviating ARCD. We selected 9 studies that had patients with ARCD and use of statins. We primarily focused on outcomes including incidence of heart failure (HF), mean changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), and end-systolic volume (LVESV) from baseline. Odds ratios (OR) were calculated using a random effect model in R-statistics. Results: Among 9 studies with a total of 2784 patients we noticed a significant reduction in the incidence of HF among patients administered statins, with an OR of 0.52 (95 % CI 0.37-0.74, p < 0.0003), indicating a substantial protective effect. However, the mean changes in EF, LVEDV, and LVESV from baseline, represented by Hedges's g of 1.09 (95 % CI -0.40 to 2.57, p = 0.15), 0.91 (95 % CI -1.69 to 3.51, p = 0.47), and 1.32 (95 % CI -2.30 to 4.94, p = 0.49) respectively, were not statistically significant. (Figure 1). Conclusion: Our meta-analysis confirms statins' effectiveness in reducing risk of ARCD. However, their influence on EF, LVEDV, and LVESV remains uncertain, warranting further study.http://www.sciencedirect.com/science/article/pii/S2666667724002423StatinsCancerAnthracyclinesCardiac DysfunctionChemotherapyHeart Failure
spellingShingle Mubashar Karamat
Bilal Hussain
Munis Mahboob Ahmed
Mohammad Hamza
Junaid Mir
Ayedh Alamri
Aimen Shafiq
Yasar Sattar
Muhammad Zia Khan
Harshith Thyagaturu
Karthik Gonuguntla
Birjesh D Patel
Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis
Statins
Cancer
Anthracyclines
Cardiac Dysfunction
Chemotherapy
Heart Failure
title Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis
title_full Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis
title_fullStr Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis
title_full_unstemmed Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis
title_short Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis
title_sort deciphering the cardioprotective effects of statins in anthracycline related cardiac dysfunction a systematic review and meta analysis
topic Statins
Cancer
Anthracyclines
Cardiac Dysfunction
Chemotherapy
Heart Failure
url http://www.sciencedirect.com/science/article/pii/S2666667724002423
work_keys_str_mv AT mubasharkaramat decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT bilalhussain decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT munismahboobahmed decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT mohammadhamza decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT junaidmir decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT ayedhalamri decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT aimenshafiq decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT yasarsattar decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT muhammadziakhan decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT harshiththyagaturu decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT karthikgonuguntla decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis
AT birjeshdpatel decipheringthecardioprotectiveeffectsofstatinsinanthracyclinerelatedcardiacdysfunctionasystematicreviewandmetaanalysis